Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Health Condition of Cannabis Consumers in the Canadian Population

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03987347
Recruitment Status : Not yet recruiting
First Posted : June 17, 2019
Last Update Posted : June 18, 2019
Sponsor:
Information provided by (Responsible Party):
Olivier Beauchet, Jewish General Hospital

Tracking Information
First Submitted Date June 13, 2019
First Posted Date June 17, 2019
Last Update Posted Date June 18, 2019
Estimated Study Start Date August 30, 2019
Estimated Primary Completion Date August 30, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: June 14, 2019)
Neurocognitive disorder [ Time Frame: around 20 years ]
The decrease of cognitive function changes the activities of daily living to older adults. Instrumental Activities of Daily Living Scale ( IADLs) will be used to assess independent living skills to people who are a diagnosis of mild cognitive impairment. A summary score range from 0 ( low function, dependent) to 8 ( high function, independent) will be given to each participant based on their daily activities.
Original Primary Outcome Measures
 (submitted: June 13, 2019)
Neurocognitive disorder [ Time Frame: around 20 years ]
The decrease of cognitive function changes the activities of daily living to older adults. The Lawton Instrumental Activities of Daily Living Scale will be used to assess independent living skills to people who are a diagnosis of mild cognitive impairment.
Change History Complete list of historical versions of study NCT03987347 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures
 (submitted: June 14, 2019)
Depression [ Time Frame: around 20 years ]
It will be used the Centre for Epidemiologic Studies-Depression Scale (CES-D) that rates how often over the past week people experience symptoms that are associated with depression. In scoring the Center for Epidemiologic Studies Depression Scale, a value of 0,1,2,3 is assigned to a response based on the emotional feelings that the participants have.
Original Secondary Outcome Measures
 (submitted: June 13, 2019)
Depression [ Time Frame: around 20 years ]
It will be used the Centre for Epidemiology Studies-Depression Scale that rates how often over the past week people experience symptoms that are associated with depression.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Health Condition of Cannabis Consumers in the Canadian Population
Official Title Health Condition of Cannabis Consumers in the Canadian Population: A Population-based Observational Cohort Study
Brief Summary This study evaluates the health condition and its evolution with time of Cannabis consumers in the Canadian population.
Detailed Description

In Canada, legalization of recreational use is likely to have decreased the perception of risks associated with Cannabis use, and means that the reported adverse effects of Cannabis are not so important, suggesting that Cannabis may be useful for their illness as an alternative or complementary therapeutic.

More Canadian physicians prescribed Cannabis for their patients. Both Recreational and medical use of Cannabis increase and will continue to grow up in the next coming years. Regardless, the typology of Cannabis use, more information on the health condition of Cannabis consumers may be helpful for the medical prescription of Cannabis, in particular in older adults who are more at risk of side effects.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population People from Canada who were enrolled in the Canadian Longitudinal Study on Aging the last 20 years, and who have consumed different cannabis products for different reasons either recreational or medical.
Condition
  • Cannabis Use
  • Old Age
  • Health Risk
Intervention Other: Observational
People who are enrolled in the Canadian Longitudinal Study on Aging. Participants undergo repeated waves of the same standardized data collection every three years. All participants are also contacted by telephone 18 months after baseline assessment to complete the Maintaining Contact Questionnaire.
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Not yet recruiting
Estimated Enrollment
 (submitted: June 13, 2019)
30000
Original Estimated Enrollment Same as current
Estimated Study Completion Date February 1, 2021
Estimated Primary Completion Date August 30, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Living in Canada the last 20 years
  • Being 60 years and over
  • Being consumer of cannabis

Exclusion Criteria:

  • Living outside Canada the last 20 years
  • Have never consumed cannabis
Sex/Gender
Sexes Eligible for Study: All
Ages 60 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Kevin Galery (+1) 514-340-8222 ext 27494 kevin.galery@mail.mcgill.ca
Listed Location Countries Canada
Removed Location Countries  
 
Administrative Information
NCT Number NCT03987347
Other Study ID Numbers 2020-1830
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party Olivier Beauchet, Jewish General Hospital
Study Sponsor Jewish General Hospital
Collaborators Not Provided
Investigators
Principal Investigator: Olivier Beauchet, MD Jewish General Hospital
PRS Account Jewish General Hospital
Verification Date June 2019